Dianthus | Affinity Screening

  • Fragment Screening: Save time and sample with Spectral Shift technology18:36

    Fragment Screening: Save time and sample with Spectral Shift technology

    Many methods used in fragment-based drug discovery pose real challenges — SPR often struggles to detect true hits due to fragments’ small mass, DSF can have high rates of false positives, and NMR equi

    Watch
  • The use of Spectral Shift in identifying Microcycle® hits for challenging therapeutic targets14:18

    The use of Spectral Shift in identifying Microcycle® hits for challenging therapeutic targets

    Transcription factors have traditionally been considered challenging therapeutic targets. Their intrinsic disorder and lack of small molecule binding pockets make them intractable to small molecule ap

    Watch
  • Measure the strength of any interaction with versatile labeling options for Spectral Shift

    Measure the strength of any interaction with versatile labeling options for Spectral Shift

    Read
  • Direct comparison of binding affinities from Spectral Shift and SPR for biotinylated targets

    Direct comparison of binding affinities from Spectral Shift and SPR for biotinylated targets

    Read
  • Three things we took away from attending Drug Discovery Chemistry in 2024

    Three things we took away from attending Drug Discovery Chemistry in 2024

    Drug Discovery Chemistry is an annual event that focuses solely on early drug discovery, where scientists from around the world gather to showcase their research and participate in thoughtful...

    Read
  • Screening for p38 ligands: From assay optimization to lead validation in 2 days12:54

    Screening for p38 ligands: From assay optimization to lead validation in 2 days

    Dianthus is a biophysical screening instrument that uses Spectral Shift technology to measure molecular interactions for hit ID, hit-to-lead, and lead optimization. It offers a 384-well plate format a

    Watch
  • Ready to tackle your challenging affinity screening?

    Discover tools you can use

    Learn more
  • Rely on Dianthus to overcome roadblocks in your PROTAC characterizations

    Rely on Dianthus to overcome roadblocks in your PROTAC characterizations

    Read
  • Applying Spectral Shift technology to study IDPs: Direct binding and displacement assays of MYC:MAX inhibitors11:48

    Applying Spectral Shift technology to study IDPs: Direct binding and displacement assays of MYC:MAX inhibitors

    MYC is an important therapeutic target that associates with MAX to regulate gene transcription. Its lack of binding pockets and the presence of disordered regions make it a difficult protein to study

    Watch
  • How to keep your degrader pipeline moving forward with Dianthus16:42

    How to keep your degrader pipeline moving forward with Dianthus

    The development of your protein degrader is a multi-step and complex process usually packed with challenges that if left unsolved will delay the progress of your project. What if you could overcome co

    Watch
  • Characterize your PROTAC hook effect with flexible and in-solution affinity measurements for results you can trust

    Characterize your PROTAC hook effect with flexible and in-solution affinity measurements for results you can trust

    Read
  • Dianthus: Tackle your most challenging affinity screenings with breakthrough Spectral Shift technology2:30

    Dianthus: Tackle your most challenging affinity screenings with breakthrough Spectral Shift technology

    Watch
  • Selective degradation of cancer target WDR5 — Evaluation of PROTACs binary and ternary affinities with Spectral Shift22:23

    Selective degradation of cancer target WDR5 — Evaluation of PROTACs binary and ternary affinities with Spectral Shift

    Chances are your company’s research and development pipeline includes several PROTAC candidates — placing you with many others in the race to bring successful and efficient protein degraders to the cl

    Watch
  • Put your challenging affinity screening campaigns back on track — after you’ve tried everything else37:25

    Put your challenging affinity screening campaigns back on track — after you’ve tried everything else

    When you’re entrusted with developing therapeutics for challenging or undruggable targets, it’s a struggle to characterize molecular interactions. And it’s not for lack of effort or expertise — SPR an

    Watch
  • NanoTemper Technologies launches Spectral Shift, a breakthrough technology that changes the game for affinity-based screenings

    NanoTemper Technologies launches Spectral Shift, a breakthrough technology that changes the game for affinity-based screenings

    NanoTemper Technologies, announced today the launch of Spectral Shift technology within their Dianthus instrument, built to handle the most challenging affinity-based screenings in drug discovery....

    Read
  • Finally tackle your most challenging affinity screenings with breakthrough Spectral Shift technology with Dianthus

    Finally tackle your most challenging affinity screenings with breakthrough Spectral Shift technology with Dianthus

    Read
  • 10 terms to help you more easily understand targeted protein degradation

    10 terms to help you more easily understand targeted protein degradation

    If you’re new to the world of TPD or you’re trying to keep up with all developments in this fast-moving field, here are some terms and definitions that will help you.

    Read
  • Top 8 targeted protein degradation conferences of 2023 at a glance

    Top 8 targeted protein degradation conferences of 2023 at a glance

    Use this downloadable list of 2023 Targeted Protein Degradation conferences to choose which one(s) to attend. Learn when and where they’ll happen, who’ll be there, and the main focus.

    Read
  • Going small to win big: Fragment-based screening in drug discovery

    Going small to win big: Fragment-based screening in drug discovery

    Read
  • 9 Targeted Protein Degradation conferences you don’t want to miss in 2022

    9 Targeted Protein Degradation conferences you don’t want to miss in 2022

    With so much interest and investment in target protein degradation, a lot can happen in a year. Here are 9 conferences to get up-to-date on recent progress and the latest approaches. You’ll not...

    Read
  • Targeted protein degradation promises to lead the way to effective drugs for challenging targets

    Targeted protein degradation promises to lead the way to effective drugs for challenging targets

    Read
  • loading
    Loading more...